Metastatic Breast Cancer, Triple Negative Breast Cancer Terminated Phase 1 Trials for Talazoparib (DB11760)

Also known as: Metastatic Triple-negative Breast Cancer / Metastatic Triple Negative Breast Cancer / Triple-negative Metastatic Breast Cancer / Triple Negative Metastatic Breast Cancer

IndicationStatusPhase
DBCOND0074793 (Metastatic Breast Cancer, Triple Negative Breast Cancer)Terminated1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02358200Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast CancerTreatment